Premium
Using of oligodendrocyte progenitors from integration‐free human induced pluripotent stem cells in treatment of spinal cord injury (89.4)
Author(s) -
Gharibani Payam,
Kerr Candace,
Gupta Siddharth,
All Angelo
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.89.4
Subject(s) - embryonic stem cell , induced pluripotent stem cell , progenitor cell , regenerative medicine , microbiology and biotechnology , biology , stem cell , neural stem cell , oligodendrocyte , kosr , directed differentiation , immunology , neuroscience , genetics , myelin , central nervous system , gene
Since the first successful derivation of induced pluripotent stem (iPS) cells, the field of regenerative medicine has grown exponentially and the goal of ‘personalized’ therapy using autologous transplants is emerging as a feasible approach. While prior studies demonstrate that human embryonic stem cells can be used to derive oligodendrocyte progenitors, there are no reports describing these cells derived from human iPS cell lines. Here, we demonstrate for the first time that oligodendrocyte progenitors (OPs) can be derived from iPS cells generated using either an episomal, non‐integrating plasmid approach or standard integrating retroviruses. The efficiency of OP differentiation ranged from 40 to 60% of total cells, which is comparable to that of human embryonic stem cells. In addition, the iPS cell lines derived using episomal vectors or retroviruses generated a similar number of early neural progenitors (NPs) and glial progenitors (GPs). We also found that the episomal plasmid‐derived iPS generated OPs expressing late OP markers (O1 and GALC), as compared to early markers (O4 and NG2), indicating that they differentiate and express mature OP markers. Moreover, we discovered that OPs derived from iPS cells engraft for over 60 days following implantation in a rat model of contusive spinal cord injury (SCI). Although further investigation is needed, these results suggest that patient‐specific, iPS‐derived OPs have potential for regenerating damaged tissue following SCI.